Compare WETH & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WETH | CYCN |
|---|---|---|
| Founded | 1992 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.5M | 16.6M |
| IPO Year | 2020 | N/A |
| Metric | WETH | CYCN |
|---|---|---|
| Price | $1.36 | $3.70 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 161.5K | 22.1K |
| Earning Date | 04-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.38 | N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $45,136,818.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.13 | ★ N/A |
| Revenue Growth | ★ 6.76 | N/A |
| 52 Week Low | $0.78 | $1.03 |
| 52 Week High | $3.68 | $8.48 |
| Indicator | WETH | CYCN |
|---|---|---|
| Relative Strength Index (RSI) | 54.60 | 62.72 |
| Support Level | $1.30 | $2.93 |
| Resistance Level | $1.48 | $3.97 |
| Average True Range (ATR) | 0.12 | 0.23 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 84.06 | 60.47 |
Wetouch Technology Inc is a business of research and development, manufacturing, and distribution of touchscreen displays to customers both in the PRC and overseas. The touchscreen products, which are manufactured by the Company, are mainly for use in financial terminals, automotive, Point of Sales, gaming, lottery, medical, Human-Machine Interface (HMI), and other specialized industries. The company sells touchscreen products both domestically in China and internationally, covering areas in Mainland China, including but not limited to the eastern, southern, northern, and southwest regions of Mainland China, Taiwan, South Korea, Germany, and other countries.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. The company focuses on enabling the full therapeutic potential of next-generation sGC stimulators and neuropsychiatric diseases. Its pipeline products include Olinciguat, Praliciguat, and others.